Christopher Cawthorne
Overview
Explore the profile of Christopher Cawthorne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
901
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spahn M, Anbuhl S, Luyten K, Loy T, Pronker M, Cawthorne C, et al.
Bioconjug Chem
. 2025 Mar;
PMID: 40067691
C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in a range of pathologies, including cancers like multiple myeloma and non-Hodgkin lymphoma, inflammatory diseases such as rheumatoid arthritis, and viral...
2.
Narykina V, Kleynhans J, Cawthorne C, Schymkowitz J, Rousseau F, Bormans G
EJNMMI Radiopharm Chem
. 2025 Feb;
10(1):10.
PMID: 39982615
Background: The extracellular localisation of the Heat shock protein 90 (Hsp90) is associated with the diseased state and wound healing and presents a promising opportunity for cancer targeting using Positron...
3.
Cuypers M, Jaspers T, Clerckx J, Leekens S, Cawthorne C, Bormans G, et al.
Fluids Barriers CNS
. 2025 Jan;
22(1):11.
PMID: 39885527
Background: Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain...
4.
Spahn M, Loy T, Celen S, Koole M, Deroose C, Cawthorne C, et al.
Eur J Nucl Med Mol Imaging
. 2024 Dec;
PMID: 39658737
Background: [Ga]PentixaFor detects C-X-C chemokine receptor type 4 (CXCR4) overexpression in various malignancies, such as multiple myeloma and non-Hodgkin lymphomas, as well as in endocrine and inflammatory disorders. This study...
5.
Munck S, De Bo C, Cawthorne C, Colombelli J
J Microsc
. 2024 Apr;
294(3):319-337.
PMID: 38683038
Developing devices and instrumentation in a bioimaging core facility is an important part of the innovation mandate inherent in the core facility model but is a complex area due to...
6.
Renaud O, Aulner N, Salles A, Halidi N, Brunstein M, Mallet A, et al.
J Microsc
. 2024 Apr;
294(3):276-294.
PMID: 38656474
Modern life science research is a collaborative effort. Few research groups can single-handedly support the necessary equipment, expertise and personnel needed for the ever-expanding portfolio of technologies that are required...
7.
Santos J, Braz M, Raposinho P, Cleeren F, Cassells I, Leekens S, et al.
Mol Pharm
. 2023 Nov;
21(1):216-233.
PMID: 37992229
Nuclear DNA is the canonical target for biological damage induced by Auger electrons (AE) in the context of targeted radionuclide therapy (TRT) of cancer, but other subcellular components might also...
8.
Ivanisevic T, Steklov M, Lechat B, Cawthorne C, Gsell W, Velde G, et al.
Cancer Commun (Lond)
. 2023 Oct;
43(12):1386-1390.
PMID: 37890861
No abstract available.
9.
Ahenkorah S, Cawthorne C, Murce E, Deroose C, Cardinaels T, Seimbille Y, et al.
Nucl Med Biol
. 2023 Apr;
118-119:108338.
PMID: 37018875
Background: [F]AlF-NOTA-octreotide is an F-labeled somatostatin analogue which is a good clinical alternative for Ga-labeled somatostatin analogues. However, radiolabeled somatostatin receptor (SSTR) antagonists might outperform agonists regarding imaging sensitivity of...
10.
Mardon K, Patel J, Savinainen J, Stimson D, Oyagawa C, Grimsey N, et al.
J Med Chem
. 2022 Dec;
66(1):538-552.
PMID: 36516997
Multimodal imaging provides rich biological information, which can be exploited to study drug activity, disease associated phenotypes, and pharmacological responses. Here we show discovery and validation of a new probe...